Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 - Ireland

SAFETY DATA SHEET



TEKNOCLAD SILVER 2125-42 - All variants

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier	
Product name	

: FEKNOCLAD SILVER 2125-42 - All variants

1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use: Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091. e-mail address of person : Prod-safe@teknos.com responsible for this SDS

National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

National advisory body/Poison Centre

- Telephone number
- Emergency medical information: (seven days) contact National Poisons Information Centre, Beaumont Hospital, Dublin 9 DOV2NO, Ireland.
 Members of the public Number (8 am-10 pm): +353 (0)1 809 2166 Healthcare professional telephone Number (24hrs): +353 (0)1 809 2566

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Skin Sens. 1, H317

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms



Signal word	:	Warning
Hazard statements	:	₩317 - May cause an allergic skin reaction.
Precautionary statements		
Prevention	:	₱280 - Wear protective gloves. P261 - Avoid breathing vapour.
Response	-	 ₱302 + P352 - IF ON SKIN: Wash with plenty of water. P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention. P362 + P364 - Take off contaminated clothing and wash it before reuse.
Storage	:	Not applicable.
Disposal	:	P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.

Date of issue/Date of revision	: 09/01/2025	Date of previous issue	:09/02/2024	Version : 1.01 1/20
FEKNOCLAD SILVER 2125-42 - A	Il variants			Label No :91193

SECTION 2: Hazards identification

Hazardous ingredients	 Contains: EO bis(benztriazolyl)phenylpropionat; Reaction mass of Bis (1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl- 4-piperidyl sebacate; 1,2-benzisothiazol-3(2H)-one and 2-methyl-2H-isothiazol-3-one
Supplemental label elements	: Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:
2.3 Other hazards	
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	: This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	: None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures	: Mixture				
Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
titanium dioxide	REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7	≤3	Carc. 2, H351 (inhalation)	-	[1] [*]
EO bis(benztriazolyl) phenylpropionat	REACH #: 01-0000015075-76 EC: 400-830-7 CAS: 104810-48-2 Index: 607-176-00-3	<1	Skin Sens. 1A, H317 Aquatic Chronic 2, H411	-	[1]
calcium bis (2-ethylhexanoate)	EC: 205-249-0 CAS: 136-51-6 Index: 607-230-00-6	<0.3	Repr. 1B, H360D	-	[1]
2-Butoxyethanol	REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0	≤0.3	Acute Tox. 4, H302 Acute Tox. 3, H331 Skin Irrit. 2, H315 Eye Irrit. 2, H319	ATE [Oral] = 1200 mg/kg ATE [Inhalation (vapours)] = 3 mg/l	[1] [2]
Reaction mass of Bis (1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl- 4-piperidyl sebacate	REACH #: 01-2119491304-40 EC: 915-687-0 CAS: 1065336-91-5	<0.1	Skin Sens. 1A, H317 Repr. 2, H361f Aquatic Acute 1, H400 Aquatic Chronic 1, H410	M [Acute] = 1 M [Chronic] = 1	[1]
1,2-benzisothiazol-3(2H)- one	EC: 220-120-9 CAS: 2634-33-5 Index: 613-088-00-6	<0.05	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Acute 1, H400	ATE [Oral] = 1020 mg/kg Skin Sens. 1, H317: C ≥ 0.05% M [Acute] = 1	[1]
pyrithione zinc	REACH #: 01-2119511196-46 EC: 236-671-3	<0.01	Acute Tox. 3, H301 Acute Tox. 2, H330 Eye Dam. 1, H318	ATE [Oral] = 221 mg/kg ATE [Inhalation	[1]
Date of issue/Date of revision FEKNOCLAD SILVER 2125-		e of previous is	sue : 09/02/2024	Version : 1.03 Label No :97119	

OFOTION A. aitian/inform

SECTION 3: Comp	osition/informat	ion on in	igreaients		
	CAS: 13463-41-7 Index: 613-333-00-7		Repr. 1B, H360D STOT RE 1, H372 Aquatic Acute 1, H400 Aquatic Chronic 1, H410	(dusts and mists)] = 0.14 mg/l M [Acute] = 1000 M [Chronic] = 10	
2-methyl-2H-isothiazol- 3-one	EC: 220-239-6 CAS: 2682-20-4	<0.0015	Acute Tox. 3, H301 Acute Tox. 3, H311 Acute Tox. 2, H330 Skin Corr. 1B, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071 See Section 16 for the full text of the H statements declared above.	ATE [Oral] = 100 mg/kg ATE [Dermal] = 300 mg/kg ATE [Inhalation (dusts and mists)] = 0.11 mg/l Skin Sens. 1, H317: C $\geq 0.0015\%$ M [Acute] = 10 M [Chronic] = 1	[1]

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter ≤ 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Skin contact	: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

SECTION 4: First aid measures

4.2 Most important symptoms and effects, both acute and delayed **Over-exposure signs/symptoms** Eye contact : No specific data. Inhalation : No specific data. **Skin contact** : Adverse symptoms may include the following: irritation redness : No specific data. Ingestion 4.3 Indication of any immediate medical attention and special treatment needed Notes to physician : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled. **Specific treatments** : No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media		
Suitable extinguishing media	:	Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	:	None known.
5.2 Special hazards arising	fron	the substance or mixture
Hazards from the substance or mixture	:	In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous combustion products	:	Decomposition products may include the following materials: metal oxide/oxides
5.3 Advice for firefighters		
Special protective actions for fire-fighters	:	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters		Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and material for	СС	ontainment and cleaning up

Small spill	: Stop leak if without risk. Move containers from spill area. Absorb with an inert
	material and place in an appropriate waste disposal container. Dispose of via a
	licensed waste disposal contractor.

Date of issue/Date of revision	: 09/01/2025	Date of previous issue	:09/02/2024	Version	:1.01	4/20
FEKNOCLAD SILVER 2125-42 - /	All variants			Label No	: <mark>91</mark> 193	3

SECTION 6: Accidental release measures

Large spill	: Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spill product. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.
6.4 Reference to other sections	: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)	
Recommendations	: Not available.
Industrial sector specific solutions	: Not available.

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

|--|

Product/ingredient name	Exposure limit values		
₽-Butoxyethanol	 NAOSH (Ireland, 4/2024) Absorbed through skin. Notes: EU derived Occupational Exposure Limit Values OELV 8 hours: 20 ppm. OELV 8 hours: 98 mg/m³. OELV 15 minutes: 50 ppm. OELV 15 minutes: 246 mg/m³. 		

Biological exposure indices

Product/ingredient name		Exposure indices			
Butoxyethanol		NAOSH (Ireland, 1/2011) BMGV: 200 mg/g creatinine, BAA [in urine]. Sampling time: end of shift - As soon as possible after exposure ceases.			
procedures European Stan assessment of values and mea atmospheres - of exposure to (Workplace atm for the measure		uld be made to monitoring standards, such as the following: dard EN 689 (Workplace atmospheres - Guidance for the exposure by inhalation to chemical agents for comparison with limit asurement strategy) European Standard EN 14042 (Workplace Guide for the application and use of procedures for the assessment chemical and biological agents) European Standard EN 482 nospheres - General requirements for the performance of procedure ement of chemical agents) Reference to national guidance methods for the determination of hazardous substances will also be			
DNELs/DMELs					
Product/ingredient name		Result			
<mark>tit</mark> anium dioxide		DNEL - General population - Long term - Inhalation 28 μg/m³ <u>Effects</u> : Local			
		DNEL - Workers - Long term - Inhalation 170 μg/m³ <u>Effects</u> : Local			
calcium bis(2-ethylhexanoate)		DNEL - General population - Long term - Oral 0.167 mg/kg bw/day <u>Effects</u> : Systemic			
		DNEL - General population - Long term - Dermal 0.167 mg/kg bw/day <u>Effects</u> : Systemic			
		DNEL - Workers - Long term - Dermal 0.333 mg/kg bw/day <u>Effects</u> : Systemic			
		DNEL - General population - Long term - Inhalation 0.58 mg/m ³ Effects: Systemic			
		DNEL - General population - Long term - Inhalation 0.66 mg/m ³ Effects: Local			
		DNEL - Workers - Long term - Inhalation 2.351 mg/m ³ Effects: Systemic			
		DNEL - Workers - Long term - Inhalation 2.66 mg/m³ <u>Effects</u> : Local			
2-Butoxyethanol		DNEL - General population - Long term - Oral 6.3 mg/kg bw/day <u>Effects</u> : Systemic			
		DNEL - General population - Short term - Oral 26.7 mg/kg bw/day <u>Effects</u> : Systemic			
		DNEL - General population - Long term - Inhalation 59 mg/m ³ <u>Effects</u> : Systemic			

: 09/01/2025 Date of previous issue

SECTION 8: Exposure controls/personal protection

Reaction mass of Bis(1,2,2,6,6-pentamethyl-

DNEL - Workers - Long term - Inhalation 98 mg/m³ Effects: Systemic

DNEL - General population - Short term - Inhalation 147 mg/m³ Effects: Local

DNEL - Workers - Short term - Inhalation 246 mg/m³ Effects: Local

DNEL - General population - Short term - Inhalation 426 mg/m³ Effects: Systemic

DNEL - Workers - Short term - Inhalation 1091 ma/m³ Effects: Systemic

DNEL - General population - Long term - Oral 0.18 mg/kg bw/day

DNEL - General population - Long term - Inhalation 0.31 mg/m³

DNEL - General population - Long term - Dermal 0.9 mg/kg bw/day

DNEL - Workers - Long term - Inhalation 1.27 mg/m³ Effects: Systemic

DNEL - Workers - Long term - Dermal 1.8 mg/kg bw/day Effects: Systemic

DNEL - General population - Long term - Dermal

DNEL - Workers - Long term - Dermal 0.966 mg/kg bw/day Effects: Systemic

DNEL - General population - Long term - Inhalation

DNEL - Workers - Long term - Inhalation

DNEL - Workers - Long term - Dermal 0.01 mg/kg bw/day Effects: Systemic

DNEL - General population - Long term - Inhalation 0.021 mg/m³ Effects: Local

DNEL - Workers - Long term - Inhalation

4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate Effects: Systemic Effects: Systemic Effects: Systemic 1,2-benzisothiazol-3(2H)-one 0.345 mg/kg bw/day Effects: Systemic 1.2 mg/m³ Effects: Systemic 6.81 mg/m³ Effects: Systemic pyrithione zinc 2-methyl-2H-isothiazol-3-one

SECTION 8: Exposure controls/personal protection

0.021 mg/m³ <u>Effects</u>: Local

DNEL - General population - Long term - Oral 0.027 mg/kg bw/day <u>Effects</u>: Systemic

DNEL - General population - Short term - Inhalation 0.043 mg/m³ <u>Effects</u>: Local

DNEL - Workers - Short term - Inhalation 0.043 mg/m³ Effects: Local

DNEL - General population - Short term - Oral 0.053 mg/kg bw/day <u>Effects</u>: Systemic

PNECs

Not available.

Appropriate engineering controls	: Cood general ventilation should be sufficient to control worker exposure to airborn contaminants.
Individual protection meas	<u>ures</u>
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period Appropriate techniques should be used to remove potentially contaminated clothin Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses wit side-shields.
Skin protection	
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard shou be worn at all times when handling chemical products if a risk assessment indicate this is necessary. Considering the parameters specified by the glove manufacture check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.
	Recommendations : Wear suitable gloves tested to EN374.
	> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm
	Not recommended polyvinyl alcohol (PVA) gloves
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other importar aspects of use.
ate of issue/Date of revision	: 09/01/2025 Date of previous issue : 09/02/2024 Version : 1.01 8/20

SECTION 8: Exposure controls/personal protection

Environmental	exposure
controls	

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

<u>Appearance</u>	
Physical state	: Liquid.
Colour	: Various
Odour	: Slight
Odour threshold	: Not available.
Melting point/freezing point	: Not available.
Initial boiling point and boiling range	:

Ingredient name	°C	°F	Method
Water	100	212	

Flammability	: Not available.
Lower and upper explosion limit	: Lower: Not applicable. Upper: Not applicable.
Flash point	: Closed cup: >100°C (>212°F)
Auto-ignition temperature	: Not available.
Decomposition temperature	: Not available.
рН	: 6.3 to 9.5
Viscosity	: Not available.
Solubility(ies)	1 · · · · · · · · · · · · · · · · · · ·
Not available.	
Solubility in water	: Not available.
Partition coefficient: n-octanol/	: Not applicable.

2

water Vapour pressure

	Va	Vapour Pressure at 20°C			Vapour pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method	
water	17.5	2.3					
elative density	: Not available.						
Density	: 1 g/cm ³						
/apour density	: Not available.						

vapour acrisity	
Particle characteristics	
Median particle size	: Not applica

9.2 Other information

9.2.1 Information with regard	d to physical hazard classes
Explosive properties	: Not available.
Oxidising properties	: Not available.
9.2.2 Other safety characteri	stics

Not applicable.

SECTION 10: Stabilit	SECTION 10: Stability and reactivity		
10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.		
10.2 Chemical stability	: The product is stable.		
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.		
10.4 Conditions to avoid	: No specific data.		
10.5 Incompatible materials	: No specific data.		
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.		

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined ir	n Regulation (EC) No 1272/2008
Acute toxicity	
Product/ingredient name	Result
Reaction mass of Bis(1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate	Rat - Oral - LD50 3230 mg/kg
	Rat - Dermal - LD50 >3170 mg/kg
1,2-benzisothiazol-3(2H)-one	Rat - Oral - LD50 1020 mg/kg
pyrithione zinc	Rat - Oral - LD50 177 mg/kg
	Rabbit - Dermal - LD50 100 mg/kg
	Rat - Inhalation - LC50 Dusts and mists 140 mg/m ³ [4 hours] <u>Toxic effects</u> : Lung, Thorax, or Respiration - Acute pulmonary edema Lung, Thorax, or Respiration - Dyspnea Gross Metabolite Changes - Weight loss or decreased weight gain
2-methyl-2H-isothiazol-3-one	Rat - Inhalation - LC50 Dusts and mists 0.11 mg/l [4 hours]

Conclusion/Summary [Product] : Not available.

Acute toxicity estimates

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
KNOCLAD SILVER 2125-42	N/A	N/A	N/A	2457.5	N/A
2-Butoxyethanol	1200	N/A	N/A	3	N/A
Reaction mass of Bis(1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate	3230	N/A	N/A	N/A	N/A
1,2-benzisothiazol-3(2H)-one	1020	N/A	N/A	N/A	N/A
pyrithione zinc	221	N/A	N/A	N/A	0.14
2-methyl-2H-isothiazol-3-one	100	300	N/A	N/A	0.11

Date of issue/Date of revision: 09/01/202IPEKNOCLAD SILVER 2125-42 - All variants

: 09/01/2025 Date of previous issue

:09/02/2024

SECTION 11: Toxicological information

Skin corrosion/irritation	
Product/ingredient name	Result
<mark>tit</mark> anium dioxide	Human - Skin - Mild irritant Duration of treatment/exposure: 72 hours Amount/concentration applied: 300 ug l
2-Butoxyethanol	Rabbit - Skin - Mild irritant Amount/concentration applied: 500 mg
1,2-benzisothiazol-3(2H)-one	Human - Skin - Mild irritant Duration of treatment/exposure: 48 hours Amount/concentration applied: 5 %
Conclusion/Summary [Product] : Not avail	able.
Serious eye damage/eye irritation	
Product/ingredient name 2-Butoxyethanol	Result Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 100 mg
	Rabbit - Eyes - Severe irritant Amount/concentration applied: 100 mg
Conclusion/Summary [Product] : Not avail	able.
Respiratory corrosion/irritation Not available.	
Conclusion/Summary [Product] : Not avail	able.
Respiratory or skin sensitization Not available.	
Skin Conclusion/Summary [Product] : Not avail	able.
Respiratory Conclusion/Summary [Product] : Not avail	able.
Germ cell mutagenicity Not available.	
Conclusion/Summary [Product] : Not avail	able.
Carcinogenicity	
	d of this product arises when respirable dust is inhaled in quantities ance mechanisms in the lung.
Conclusion/Summary [Product] : Not avail	able.
Reproductive toxicity Not available.	
Date of issue/Date of revision : 09/01/2025 Date EKNOCLAD SILVER 2125-42 - All variants	te of previous issue : 09/02/2024 Version : 1.01 11/20 Label No : 91 193

SECTION 11: Toxicological information

Conclusion/Summary [Product] : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure) Product/ingredient name Result Writhione zinc STOT RE 1, H372 Aspiration hazard Not available. Potential acute health effects Potential acute health effects Potential acute health effects No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : May cause an allergic skin reaction. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical. chemical and toxicological characteristics Eye contact Skin contact : No specific data. Inhalation : Mo specific data. Skin contact : Ro specific data. Ingestion : Mo specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. Conclusion/Summary (Product]	Specific target organ toxicit	w (ropoa	tod ovposuro)
Firsthione zinc STOT RE 1, H372 Aspiration hazard Not available. Information on likely routes of exposure Not available. Potential acute health effects Potential acute health effects Eye contact :: No known significant effects or critical hazards. Inhalation :: No known significant effects or critical hazards. Skin contact :: No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact :: No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact :: No specific data. Inhalation :: Mo specific data. : More specific data. : More specific data. Skin contact :: More specific data. : More specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure : More specific data. Potential immediate : Not available. : More specific data. Effects : Not available. : More specific data. Potential immediate : Not available. : More specific data. Endition mediate : Not available. : More specific data. Econteme exposure : More value infec		y (repea	
Assiration hazard Not available. Information on likely routes of exposure Not available. Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : May cause an allergic skin reaction. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : No specific data. Skin contact : Moy expecific data. Delaved and immediate officets as well as chronic effects from short and long-term exposure Short term exposure Potential delayed effects : Not available. effects Potential delayed effects : Not available. effects Potential delayed effects : Not available. effects Potential delayed effects : Not available. Potential delayed effects : Not available. effects Potential delayed effects : Not available. Conclusion/Summary [Product] : Not available. General : One sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Nut available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the orderia set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.			
Not available. Information on Ilkely routes of exposure Not available. Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : May cause an allergic skin reaction. Ingestion :: No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Skin contact : No specific data. Skin contact : Mo specific data. Skin contact : Mo specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Potential immediate : Not available. effects : Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity : Not available. Carcinogenicity : Not available. Carcinogenicity : Not available.	pynanono zino		
Information on likely routes of exposure Not available. Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : May cause an allergic skin reaction. Ingestion : Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Skin contact : Moverse symptoms may include the following: irritation rediness Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. effects : Not available. Potential chaloge effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical h	Aspiration hazard		
Not available. Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : May cause an allergic skin reaction. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Mo specific data. Skin contact : Mo specific data. Skin contact : Mo specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential effects Potential delayed effects : Not available. effects : Not available. effects : Not available. Potential delayed effects : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Nutagenicity : No known signi	Not available.		
Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : May cause an allergic skin reaction. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : No specific data. Skin contact : More symptoms may include the following: irritation irritation redness Ingestion :: No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure : Not available. effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Reproductive toxicity :	Information on likely routes	of expo	<u>sure</u>
Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : May cause an allergic skin reaction. Ingestion : No known significant effects or critical hazards. Symptoms rolated to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Mo specific data. Inhalation : Mo specific data. Skin contact : Specific data. Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : Not available. Conclusion/Summary [Product] : Not available. Carcino	Not available.		
Inhalation : No known significant effects or critical hazards. Skin contact : May cause an allergic skin reaction. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Mo specific data. Inhalation : Mo specific data. Skin contact : Mo specific data. Ingestion : Mo specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure - Mot available. Potential immediate : Not available. Long term exposure - Not available. Potential delayed effects : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. Mutagenicity : No known signifi	Potential acute health effect	<u>ts</u>	
Skin contact : May cause an allergic skin reaction. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Mo specific data. Skin contact : Mo specific data. Skin contact : Mo specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Onc available. Potential chronic health effects : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.	Eye contact	: No k	nown significant effects or critical hazards.
Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Mo specific data. Skin contact : Moverse symptoms may include the following: irritation redness Ingestion : Moverse symptoms may include the following: irritation redness Ingestion : Mo specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. Long term exposure : Not available. Potential immediate : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Carcinogenicity : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. 11.2.1	Inhalation	: No k	nown significant effects or critical hazards.
Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : No specific data. Skin contact : No specific data. Ingestion : No specific data. Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential limmediate : Not available. effects Potential delayed effects : Not available. Potential chronic health effects : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 112.1nformation on other hazards : No known significant effects or critical hazards. Nutagenicity : No known significant effects or critical hazards.	Skin contact	: May	cause an allergic skin reaction.
Eye contact : No specific data. Inhalation : No specific data. Skin contact : Adverse symptoms may include the following: inflation redness Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. Not available. : Not available. Carcinogenicity : No known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. <td>Ingestion</td> <td>: No k</td> <td>nown significant effects or critical hazards.</td>	Ingestion	: No k	nown significant effects or critical hazards.
Inhalation IN ospecific data. Skin contact IN ospecific data. Skin contact IN ospecific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate IN ot available. effects IN ot available. Potential delayed effects IN to available. effects IN ot available. Potential delayed effects IN to available. effects IN ot available. Potential chronic health effects IN ot available. Potential chronic health effects IN ot available. Conclusion/Summary [Product] IN to available. General Conclusion/Summary [Product] Carcinogenicity IN ok known significant effects or critical hazards. Mutagenicity IN ok known significant effects or critical hazards. Reproductive toxicity IN ok known significant effects or critical hazards. 11.2 Information on other hazards Incernical becoming upporties Not available. Conclusion/Summary [Product] Conclusion/Summary [Product] IN or known significant effects or critical hazards. Mutagenicity IN ok known significant effects or critical hazards. <td>Symptoms related to the ph</td> <td>ysical, c</td> <td>hemical and toxicological characteristics</td>	Symptoms related to the ph	ysical, c	hemical and toxicological characteristics
Skin contact : Moverse symptoms may include the following: irritation redness Ingestion : Mo specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. Long term exposure Potential delayed effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : Wo known significant effects or critical hazards. Not available. : No known significant effects or critical hazards. Reproductive toxicity : Wo known significant effects or critical hazards. Reproductive toxicity : Wo known significant effects or critical hazards. Not av	Eye contact	: No s	pecific data.
irritation redness Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential delayed effects : Not available. Long term exposure Potential delayed effects : Not available. effects Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	Inhalation	: No s	pecific data.
Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential delayed effects : Not available. effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards Intermediate of the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No 1907/2008. Not available. : The product does not meet the criteria to be considered as having end	Skin contact	: Adve	erse symptoms may include the following:
Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Potential delayed effects : Not available. effects : Potential immediate : Not available. effects : Potential delayed effects : Not available. effects : Potential chronic health effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Not available. : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards.			
Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. effects Potential delayed effects : Not available. Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. : Mo known significant effects or critical hazards. Not available. : Mo known significant effects or critical hazards. 11.2. Information on other hazards : Mo known significant effects or critical hazards.	Incretion		
Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No 1272/2008. 11.2.2 Other information : 1907/2006 or Regulation (EC) No 1272/2008.	-		•
Potential immediate : Not available. effects : Not available. Long term exposure . Potential delayed effects : Not available. effects : Not available. effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. 11.2 Information on other hazards . Not available. . Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information :		<u>cts as w</u>	en as chronic effects from snort and long-term exposure
effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. 11.2 Information on other hazards Ince sensitized, as not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No. 1272/2008. 11.2.2 Other information Information		. NI. (
Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : Not known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. 11.2.1 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2008 or Regulation (EC) No 1272/2008. 11.2.2 Other information United matching the product of the criteria set out in either Regulation (EC) No. 1907/2008.		: NOT	avaliable.
Long term exposure Potential immediate : Not available. effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2.1 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information United to the criteria set out in either Regulation (EC) No 1272/2008.		: Not	available.
Potential immediate : Not available. effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2.1 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information			
Potential delayed effects : Not available. Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : The product does not meet the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.		: Not	available.
Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : Mo known significant effects or critical hazards. 11.2 Information on other hazards Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information Information (EC) No 1272/2008.	effects		
Not available. Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information Information (EC) No 1272/2008.			available.
Conclusion/Summary [Product] : Not available. General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards Mo known significant effects or critical hazards. 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : Information		<u>ects</u>	
General : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards : No known significant effects or critical hazards. 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : Information (EC) No 1272/2008.	Not available.		
to very low levels. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : Information	Conclusion/Summary [Pro	oduct]	: Not available.
Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	General		
Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	Carcinogenicity	: No k	nown significant effects or critical hazards.
 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information 	Mutagenicity	: No k	nown significant effects or critical hazards.
 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information 	Reproductive toxicity	: <mark>N</mark> o k	nown significant effects or critical hazards.
 Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information 			ies
 Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information 			
disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information		oduct1	. The product does not meet the criteria to be considered as having endocrine
			disrupting properties according to the criteria set out in either Regulation (EC)
Not available.	11.2.2 Other information		
	Not available.		

SECTION 12: Ecological information

12.1 Toxicity Product/ingredient name

titanium dioxide

2-Butoxyethanol

Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate

1,2-benzisothiazol-3(2H)-one

pyrithione zinc

Result

Acute - LC50 - Marine water

Fish - Mummichog - *Fundulus heteroclitus* >100000 µg/l [96 hours] <u>Effect</u>: Mortality

Acute - LC50 - Fresh water

Crustaceans - Water flea - *Ceriodaphnia dubia* - Neonate <u>Age</u>: <24 hours 3 mg/l [48 hours] <u>Effect</u>: Mortality

Acute - LC50 - Marine water

Fish - Inland silverside - *Menidia beryllina* <u>Size</u>: 40 to 100 mm 1250000 μg/l [96 hours] <u>Effect</u>: Mortality

Acute - LC50 - Marine water

Crustaceans - Common shrimp, sand shrimp - *Crangon crangon* 800000 µg/l [48 hours] <u>Effect</u>: Mortality

Acute - LC50

OECD [Fish, Acute Toxicity Test] Fish - *Brachydanio rerio* 0.9 mg/l [96 hours]

EC50

OECD [Alga, Growth Inhibition Test] Aquatic plants - *Desmodesmodus subspicatus* 1.68 mg/l [72 hours]

Chronic - NOEC

OECD [Daphnia Magna Reproduction Test] Daphnia - Daphnia 1 mg/l [21 days]

Acute - LC50 - Fresh water

OECD [Fish, Acute Toxicity Test] Fish - Trout - *Onorhynchus Mykiss* 1.9 mg/l [96 hours]

Acute - EC50

OECD 202 [Daphnia sp. Acute Immobilization Test and Reproduction Test] Daphnia - Daphnia - *Daphnia Magna* 3.7 mg/l [48 hours]

Acute - EC50 - Marine water

OECD 201 [Alga, Growth Inhibition Test] Algae - Algae - *Skeletonema Costatum* 0.36 mg/l [72 hours]

Acute - NOEC - Marine water OECD 201 [Alga, Growth Inhibition Test] Algae - Algae - *Skeletonema Costatum* 0.15 mg/l [72 hours]

Acute - EC50 - Marine water Algae - Diatom - *Thalassiosira pseudonana* 0.51 μg/l [96 hours]

Date of issue/Date of revision: 09/01/2025♥EKNOCLAD SILVER 2125-42 - All variants

Date of previous issue

:09/02/2024

Version : 1.01 13/20 Label No : 91193

SECTION 12: Ecological information	
	Effect: Population
	Chronic - EC10 - Marine water Algae - Diatom - <i>Thalassiosira pseudonana</i> 0.36 μg/l [96 hours] <u>Effect</u> : Population
	Chronic - NOEC - Fresh water US EPA Daphnia - Water flea - <i>Daphnia magna</i> 2.7 ppb [21 days] <u>Effect</u> : Growth
	Acute - EC50 - Fresh water US EPA Daphnia - Water flea - <i>Daphnia magna</i> <u>Age</u> : <24 hours 8.25 ppb [48 hours] <u>Effect</u> : Intoxication
	Acute - LC50 - Fresh water US EPA Fish - Fathead minnow - <i>Pimephales promelas</i> <u>Weight</u> : 0.28 g 2.68 ppb [96 hours] <u>Effect</u> : Mortality
2-methyl-2H-isothiazol-3-one	Acute - EC50 - Fresh water US EPA Daphnia - Water flea - <i>Daphnia magna</i> <u>Age</u> : <24 hours 0.18 ppm [48 hours] <u>Effect</u> : Intoxication
	Acute - LC50 - Fresh water US EPA Fish - Rainbow trout,donaldson trout - <i>Oncorhynchus mykiss</i> <u>Weight</u> : 0.73 g 0.07 ppm [96 hours] <u>Effect</u> : Mortality
Conclusion/Summary [Product] : Not availa	able.

12.2 Persistence and degradability

Product/ingredient name	Result
₱ ₱ ₱ ₱ ₱ ₱ ₱ ₱ ₱ ₱ ₱ ₱ ₱ ₱	EU
	24% [28 days]

Conclusion/Summary [Product] : Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
7,2-benzisothiazol-3(2H)-one	-	-	Inherent

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
calcium bis (2-ethylhexanoate)	-	2.96	Low
	0.81	- 3.2	Low Low
pyrithione zinc	0.9	11	Low

: 09/01/2025 Date of previous issue

:09/02/2024

SECTION 12: Ecological information

12.4 Mobility in soil

Soil/water partition coefficient

Product/ingredient name	logKoc	Кос	
calcium bis(2-ethylhexanoate)	1.82	66.4852	
2-Butoxyethanol	1.83	67.3685	
1,2-benzisothiazol-3(2H)-one	1.86	73.142	
2-methyl-2H-isothiazol-3-one	1.74	54.9187	

Results of PMT and vPvM assessment

Product/ingredient name	РМТ	Р	М	Т	vPvM	vP	٧M
ti tanium dioxide	No	No	No	No	No	No	No
EO bis(benztriazolyl) phenylpropionat	No	No	No	No	No	No	No
calcium bis (2-ethylhexanoate)	No	No	No	No	No	No	No
2-Butoxyethanol	No	No	No	No	No	No	No
Reaction mass of Bis (1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl- 4-piperidyl sebacate	No	No	No	No	No	No	No
1,2-benzisothiazol-3(2H)-one	No	No	No	No	No	No	No
pyrithione zinc	No	No	No	No	No	No	No
2-methyl-2H-isothiazol-3-one	No	No	No	No	No	No	No
Mobility	: Not ava	ailable.					

Mobility Conclusion/Summary

. Not

: The product does not meet the criteria to be considered as a PMT or vPvM.

12.5 Results of PBT and vPvB assessment
Regulation (EC) No. 1907/2006 [REACH]

Product/ingredient name	PBT	Р	В	Т	vPvB	vP	vB
intanium dioxide	No	No	No	No	No	No	No
EO bis(benztriazolyl) phenylpropionat	No	No	No	No	No	No	No
calcium bis (2-ethylhexanoate)	No	No	No	No	No	No	No
2-Butoxyethanol	No	No	No	No	No	No	No
Reaction mass of Bis (1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl- 4-piperidyl sebacate	No	No	No	No	No	No	No
1,2-benzisothiazol-3(2H)-one	No	No	No	No	No	No	No
pyrithione zinc	No	No	No	No	No	No	No
2-methyl-2H-isothiazol-3-one		No	No	No	No	No	No

Regulation (EC) No. 1272/2008 [CLP]

Product/ingredient name	PBT	Р	В	т	vPvB	vP	vB
titanium dioxide	No	No	No	No	No	No	No
EO bis(benztriazolyl) phenylpropionat	No	No	No	No	No	No	No
calcium bis (2-ethylhexanoate)	No	No	No	No	No	No	No
2-Butoxyethanol	No	No	No	No	No	No	No
Reaction mass of Bis (1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-	No	No	No	No	No	No	No

Date of issue/Date of revision

: 09/01/2025 Date of previous issue

:09/02/2024

Version : 1.01 15/20 Label No :91193

FEKNOCLAD SILVER 2125-42 - All variants

SECTION 12: Ecological information								
4-piperidyl sebacate								
1,2-benzisothiazol-3(2H)-one	No							
pyrithione zinc	No							
2-methyl-2H-isothiazol-3-one	No							

Conclusion/Summary Regulation (EC) No. 1272/2008 [CLP] : The product does not meet the criteria to be considered as a PBT or vPvB.

12.6 Endocrine disrupting properties

Not available.

Conc	lusior	n/Summai	ry [Produ	ct]

: The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment meth	ods
Product	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions	This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	ADN	IMDG	IATA		
14.1 UN number or ID number	Not regulated.	9006	Not regulated.	Not regulated.		
14.2 UN proper shipping name	-	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.	-	-		
14.3 Transport hazard class(es)	-	9	-	-		
14.4 Packing group	-	-	-	-		
14.5 Environmental hazards	No.	Yes.	No.	No.		

Additional information

SECTION 14: Transport information				
ADN	: The product is only regulated as a dangerous good when transported in tank vessels.			
14.6 Special precautions for user	: Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.			
14.7 Maritime transport in bulk according to IMO instruments	: Not relevant/applicable due to nature of the product.			

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>EU Regulation (EC) No. 1907/2006 (REACH)</u>

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Product/ingredient name	%	Designation [Usage]
FEKNOCLAD SILVER 2125-42	≥90	3

Labelling	:	
Other EU regulations		
Industrial emissions (integrated pollution prevention and control) - Air	:	Not listed
Industrial emissions (integrated pollution prevention and control) - Water	:	Not listed
Explosive precursors	:	Not applicable.
Ozone depleting substance	es	<u>(EU 2024/590)</u>
Not listed.		
Prior Informed Consent (P Not listed.	<u>IC)</u>	<u>(649/2012/EU)</u>
Persistent Organic Polluta Not listed.	nts	<u>8</u>
Seveso Directive		
This product is not controlled	l u	nder the Seveso Directive.
International regulations		
Chemical Weapon Conventi	on	List Schedules I, II & III Chemicals
Not listed.		
Montreal Protocol		
Not listed.		
Stockholm Convention on F		reistant Organia Pollutanta
Stockholm Convention on F Not listed.	er	Sistem Organic Fonutants
Rotterdam Convention on P	ric	or Informed Consent (PIC)
Date of issue/Date of revision		: 09/01/2025 Date of previous issue

:09/02/2024

SECTION 15: Regulatory information

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

15.2 Chemical safety assessment

: This product contains substances for which Chemical Safety Assessments are still required.

SECTION 16: Other information

Indicates information	that has changed from previously issued version.
Abbreviations and	: ATE = Acute Toxicity Estimate
acronyms	CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.
	1272/2008]
	DMEL = Derived Minimal Effect Level
	DNEL = Derived No Effect Level
	EUH statement = CLP-specific Hazard statement
	N/A = Not available
	PBT = Persistent, Bioaccumulative and Toxic
	PNEC = Predicted No Effect Concentration
	RRN = REACH Registration Number
	SGG = Segregation Group
	vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification	
Skin Sens. 1, H317	Calculation method	

Full text of abbreviated H statements

H 301	Toxic if swallowed.
H302	Harmful if swallowed.
H311	Toxic in contact with skin.
H314	Causes severe skin burns and eye damage.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H331	Toxic if inhaled.
H351	Suspected of causing cancer.
H360D	May damage the unborn child.
H361f	Suspected of damaging fertility.
H372	Causes damage to organs through prolonged or repeated exposure.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
EUH071	Corrosive to the respiratory tract.

Full text of classifications [CLP/GHS]

Acute Tox. 2	ACUTE TOXICITY - Category 2
Acute Tox. 3	ACUTE TOXICITY - Category 3
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Aquatic Chronic 2	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2
Carc. 2	CARCINOGENICITY - Category 2
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Repr. 1B	REPRODUCTIVE TOXICITY - Category 1B
Repr. 2	REPRODUCTIVE TOXICITY - Category 2
Skin Corr. 1B	SKIN CORROSION/IRRITATION - Category 1B
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
Skin Sens. 1A	SKIN SENSITISATION - Category 1A
1	

SECTION 16: Other information				
STOT RE 1	SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 1			
Date of issue/ Date of revision	: 09/01/2025			
Date of previous issue	e : 09/02/2024			
Version	: 1.01 KNOCLAD SILVER 2125-42 All variants			
Notice to reader				

Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision: 09/01/2025DatePEKNOCLAD SILVER 2125-42 - All variants

: 09/01/2025 Date of previous issue

:09/02/2024

Version : 1.01 20/20 Label No : 91193